Università degli Studi di Milano

Lead scientists: Agostino Riva, Valeria Calcaterra, Massimo Galli, Gian Vincenzo Zuccotti, Maciej Tarkowski, Alessia Lai, Gianguglielmo Zehender, Arianna Gabrieli, Elisa Borghi, Valentina Massa

The University of Milan was founded in 1924, it is a research-intensive university, offering high quality teaching at all levels in a broad spectrum of fields, including medicine. 

The ‘Luigi Sacco’ Department of Biomedical and Clinical Sciences (DIBIC) is a teaching and research institution of the University of Milan.
“Luigi Sacco University Hospital “ is a general hospital located in Milan, it is a public hospital dedicated to patients’ care, education and training and to research. LSUH is peculiarly dedicated to infectious diseases and is the reference center for emerging and highly contagious diseases in Northern Italy.

The III Division of infectious diseases within DIBIC is a Clinic highly specialized in ID for inpatients and outpatients care and consultancies and it is strictly connected to the Laboratory of Infectious Diseases focused on research in the fields of HIV, HCV, HBV, emerging infectious diseases, host and viral genetics and immunology in ID and vaccine research.

The Laboratory is fully equipped to apply the most advanced techniques in cellular and molecular biology. The laboratory is divided into two structurally and functionally separated units closely interacting, one designated to cell culturing, virus isolating, serology and immunophenotypic analyses; the other assigned to nucleic acids amplification and sequencing. Since the appearance of COVID 19 pandemic, the III Division of Infectious Diseases has been fully dedicated to patients’ assistance and to basic and clinical research.

Roles in the COVICS project:
  • Participant in WP1
  • Contribution to General Population Cohorts (WP2)
  • Contribution to the cohort studies on targeted population (WP3)
  • Contribution to Children Cohorts (WP4)
  • Contribution to Genomic and Virologic Surveillance (WP5)
  • Contribution to Immune Surveillance (WP6)

CoVICIS is funded by the European Union’s Horizon Europe Research and Innovation Programme under grant nr 101046041